Sebetralstat for breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis in KONFIDENT-S.

Publication Title

J Allergy Clin Immunol Glob

Authors

• Tamar Kinaciyan
• Emel Aygören-Pürsün
• Inmaculada Martinez-Saguer
• Daniel F Soteres
• Daisuke Honda
• Michael E Manning
• H James Wedner
• Atsushi Fukunaga
• Henry J Kanarek
• Kazumasa Ohmura
• Isaac Melamed
• Tariq El-Shanawany
• Laurence Bouillet
• William R Lumry
• Marc A Riedl
• Majed Koleilat
• Bob Geng
• Isao Ohsawa
• Noemi Bara
• Syed Rehman
• Jonathan A Bernstein
• Paula J Busse
• Mauro Cancian
• Danny M Cohn
• Timothy J Craig
• Henriette Farkas
• Sorena Kiani-Alikhan
• H Henry Li
• Jason P Raasch
• Raffi Tachdjian, Allergy and Immunology, Providence Saint John's Health Center, Santa Monica, CA USA
• Paul K Audhya
• Paolo Bajcic
• Ya-Hsiu Chuang
• Matthew Iverson
• Michael D Smith
• Christopher M Yea
• Andrea Zanichelli

Document Type

Article

Publication Date

9-1-2026

Keywords

california; santa monica; psjhc

Abstract

Background: Although long-term prophylaxis (LTP) reduces attack frequency in hereditary angioedema, patients may experience breakthrough attacks. Oral sebetralstat demonstrated favorable safety and efficacy compared with placebo in the randomized phase 3 KONFIDENT trial (NCT05259917), including in patients receiving LTP. The safety and effectiveness of sebetralstat in participants receiving LTP are being assessed in the KONFIDENT-S open-label extension study (NCT05505916).

Objective: This interim analysis of the KONFIDENT-S study evaluated long-term safety and effectiveness of oral sebetralstat 600 mg for attacks of hereditary angioedema with C1-inhibitor deficiency in participants receiving LTP with lanadelumab, berotralstat, or C1 inhibitor.

Methods: Efficacy end points included times to beginning of symptom relief, reduction in severity, and complete attack resolution.

Results: As of September 14, 2024, 35 participants receiving LTP experienced a mean ± standard deviation of 1.7 ± 1.5 attacks per month and treated 382 attacks with sebetralstat (1.3 ± 1.1 sebetralstat-treated attacks per month). Median (interquartile range) time from attack recognition to sebetralstat administration was 6 (1-40) minutes; time to beginning of symptom relief was 1.3 (0.8 to 3.8) hours, time to reduction in severity was 4.2 (1.3 to >12) hours, and time to complete attack resolution was 14.8 (4.6 to >24) hours. Effectiveness was similar for participants receiving berotralstat, lanadelumab, or C1 inhibitor. No serious or severe treatment-related treatment-emergent adverse events were reported.

Conclusion: Sebetralstat was well tolerated and enabled early on-demand treatment of attacks in patients with hereditary angioedema with C1-inhibitor deficiency receiving LTP. Treatment of breakthrough attacks with sebetralstat resulted in rapid symptom relief, reduction in attack severity, and complete attack resolution, regardless of LTP mechanism of action.

Specialty/Research Institute

Allergy & Immunology

DOI

10.1016/j.jacig.2026.100750